Drug Information

Drug General Information
Drug ID
D0I7PU
Former ID
DNCL003464
Drug Name
Lirilumab
Drug Type
Monoclonal antibody
Indication Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] Phase 2 [525244]
Company
Bristol-Myers Squibb
Target and Pathway
Target(s) KIR Target Info Modulator [544394]
NetPath Pathway FSH Signaling Pathway
IL4 Signaling Pathway
References
Ref 525244ClinicalTrials.gov (NCT02481297) Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
Ref 544394Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model. J Immunother Cancer. 2013; 1(Suppl 1): P40.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.